Ignite Creation Date:
2025-12-25 @ 2:23 AM
Ignite Modification Date:
2026-03-09 @ 5:56 AM
Study NCT ID:
NCT04147234
Status:
COMPLETED
Last Update Posted:
2025-08-19
First Post:
2019-10-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-03
Start Date Type:
ACTUAL
Primary Completion Date:
2022-11-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2024-03-21
Completion Date Type:
ACTUAL
First Submit Date:
2019-10-30
First Submit QC Date:
None
Study First Post Date:
2019-11-01
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2025-03-20
Results First Submit QC Date:
None
Results First Post Date:
2025-06-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-18
Last Update Post Date:
2025-08-19
Last Update Post Date Type:
ACTUAL